Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis
about
sameAs
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statementNon steroidal anti-inflammatory drugs (NSAID) and aspirin for preventing colorectal adenomas and carcinomasPreferred reporting items for systematic reviews and meta-analyses: the PRISMA statementAspirin chemoprevention in patients with increased risk for colorectal cancer: a cost-effectiveness analysisCalibration methods used in cancer simulation models and suggested reporting guidelinesColorectal cancer predicted risk online (CRC-PRO) calculator using data from the multi-ethnic cohort study.Individualizing colonoscopy screening by sex and race.Prevention, screening and treatment of colorectal cancer: a global and regional generalized cost effectiveness analysis.Cost-effectiveness of aspirin adjuvant therapy in early stage colorectal cancer in older patients.Can calcium chemoprevention of adenoma recurrence substitute or serve as an adjunct for colonoscopic surveillance?Cost-effectiveness of colorectal cancer screening in high-risk Spanish patients: use of a validated model to inform public policyAs tests evolve and costs of cancer care rise: reappraising stool-based screening for colorectal neoplasiaOption appraisal of population-based colorectal cancer screening programmes in England.Review article: the potential of combinational regimen with non-steroidal anti-inflammatory drugs in the chemoprevention of colorectal cancer.A systematic comparison of microsimulation models of colorectal cancer: the role of assumptions about adenoma progression.Chemoprevention of colorectal cancer with nonsteroidal anti-inflammatory drugs.Association of stem-like cells in gender-specific chemoprevention against intestinal neoplasia in MIN mouse.Chemoprevention of colorectal cancer: two steps forward, one step back?Patient preferences for the chemoprevention of colorectal cancer.Willingness to pay for cancer prevention.Chemopreventive effect of nonsteroidal anti-inflammatory drugs on the development of a new colorectal polyp or adenoma in a high-risk population: a meta-analysis.Oral bisphosphonates and colorectal cancer.The role of low-dose aspirin in the prevention of colorectal cancer.Safety, efficacy and costs of pharmacotherapy for functional gastrointestinal disorders: the case of alosetron and its implications.Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study.Serological testing for coeliac disease in patients with symptoms of irritable bowel syndrome: a cost-effectiveness analysis.Cost-effectiveness of colorectal cancer screening with computed tomography colonography: the impact of not reporting diminutive lesions.Colon cancer: preventive agents and the present status of chemoprevention
P2860
Q21562278-0BB6D995-B0C0-42B9-B83C-F2D37DDA543CQ24247367-03553C60-DFE4-4A60-B774-A790A525AC8FQ27860868-5D6F34AA-E88B-4C91-B0EF-01B0F3CFDD0FQ28218533-8B0AF1F9-E8DB-4C62-8331-02EB9FD5792FQ28749665-D2B52C3F-E688-49A3-BDA6-0F292A5CCA96Q30726318-18EE4518-225C-4E01-B314-7972FA3621F7Q33588581-7135E3B2-8CC3-4009-A520-EE2C4DB1B38FQ33774326-4854BCBB-3960-41FB-9330-AAD57AEE0D9AQ34251380-DD925DC4-9AFE-4E0A-B730-AAF99302CDD1Q34275436-57F23729-02B1-4E16-B785-4B90E51CF62EQ35173359-7B2832AA-0C06-4634-B5E9-509E873BE7EDQ35206019-DB95A092-4A18-424A-B02E-18B7B3D3FB0BQ35929500-553F94D8-ACD5-469D-A7EF-511569BCD544Q36041152-88E17F57-2894-496F-91F9-70570B368F7FQ36180124-88817A44-E520-4CAD-98CF-08982F04770DQ36367822-D82FA6C6-21EA-4AB0-8875-D59F17D39E1BQ36570730-59E351C9-6462-44D3-94CA-C1D6BFC9C809Q36677468-F4BCB502-D8DF-4C78-9F84-10E7D05BFBEDQ37080424-227A1E03-1583-444F-BD34-433A22E4BA63Q37503094-0B56EED6-1A9A-44D8-8C78-06AF509FE8C4Q37661099-A88928AE-A8F9-4B67-B01B-FD0F97C2F4C6Q37692229-187F0447-DA02-498C-830D-82C27A60DA4DQ37982139-523EACEC-2E74-4E74-A102-E31CB1EA8291Q39396013-A39170CD-709B-4868-8A06-AA1EE50EAB33Q42035537-CD9CCE45-217C-4FB3-908D-53B9AE2D5F59Q44135004-92EB25C7-A9C6-41F4-97B2-2756EA7658EDQ45937579-D2C5633D-5103-43D8-9843-15F601CBCD46Q53485684-0AEC4B5B-716C-4E78-A34D-7104EE00EB72Q54172424-40CF5E68-63D8-4951-BF3F-347F251C2770
P2860
Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Aspirin as an adjunct to scree ...... A cost-effectiveness analysis
@ast
Aspirin as an adjunct to scree ...... A cost-effectiveness analysis
@en
Aspirin as an adjunct to scree ...... A cost-effectiveness analysis
@nl
type
label
Aspirin as an adjunct to scree ...... A cost-effectiveness analysis
@ast
Aspirin as an adjunct to scree ...... A cost-effectiveness analysis
@en
Aspirin as an adjunct to scree ...... A cost-effectiveness analysis
@nl
prefLabel
Aspirin as an adjunct to scree ...... A cost-effectiveness analysis
@ast
Aspirin as an adjunct to scree ...... A cost-effectiveness analysis
@en
Aspirin as an adjunct to scree ...... A cost-effectiveness analysis
@nl
P2093
P1476
Aspirin as an adjunct to scree ...... A cost-effectiveness analysis
@en
P2093
A M Fendrick
C L Chopra
J M Scheiman
M E Chernew
U Ladabaum
P304
P356
10.7326/0003-4819-135-9-200111060-00007
P407
P577
2001-11-06T00:00:00Z